Search
TSHA-118
go.drugbank.com/drugs/DB16996ExperimentalTSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.
TP-252
go.drugbank.com/drugs/DB17912ExperimentalTP-252 consists of magnesium L-lysinate bis-eicosapentaenoate, an ionizable salt of eicosapentaenoic acid (EPA), currently being investigated to treat familial adenomatous polyposis.[A259956]
Synonyms: Magnesium, bis(l-lysinato-.kappa.n2,.kappa.o1)-, (t-4)-, (5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoate (1:2)SPH-3127
go.drugbank.com/drugs/DB19108InvestigationalSPH-3127 is under investigation in clinical trial NCT05359068 (Study to Evaluate the Efficacy and Safety of SPH3127 in Patients With Mild-moderate Essential Hypertension).
Etilefrine
go.drugbank.com/drugs/DB08985ApprovedWithdrawnEtilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.
BMS-986020
go.drugbank.com/drugs/DB14948InvestigationalBMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy
Modakafusp alfa
go.drugbank.com/drugs/DB16399InvestigationalModakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory
Bencyclane
go.drugbank.com/drugs/DB13488ExperimentalA vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects.
CoviGlobulin
go.drugbank.com/drugs/DB15747ExperimentalThe antibodies themselves are produced in response to an immunogen and derived from antibody-producing plasma cells that were once B-cell clones. … Rabbit polyclonal antibodies are derived from the rabbit, a common animal host for polyclonal production.
GX-19 Vaccine
go.drugbank.com/drugs/DB15891InvestigationalAs of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488]. … The GX-19 vaccine is a DNA vaccine created by Genexine, Inc. Company in Gyeonggi, Korea[A219758].
Bleomycin A6
go.drugbank.com/drugs/DB12992InvestigationalIt was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment. … The development of this drug, apparently, was discontinued.